

Cover Story
Regulatory News
The FDA Oncologic Drugs Advisory Committee agreed with the agency’s forcefully stated view that Lynparza (olaparib), a PARP inhibitor, should be given only to metastatic castration-resistant prostate cancer patients whose tumors have a BRCA mutation.
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets
NCI Trials


NCI Trials for May 2023
The National Cancer Institute approved the following clinical research studies last month. Â
Trending Stories
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - Banished from the institute he founded, separated from his lab materials, Tom Curran sues Children’s Mercy
Whistleblower lawsuit alleges wrongful firing - ACOG says it will no longer accept federal funding
- Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- Lou Weiner: Poetry and art help us imagine my mother’s world as a hidden child of the Holocaust